Tachykinin NK1 receptor antagonists for the control of chemotherapy-induced nausea and vomiting

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 12, 2001, Pages 1837-1847

  Gale, J D ^a   O'Neill, B T ^a   Humphrey, J M ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Emesis; Nausea; NK1; Substance P; Tachykinin; Tachykinin receptor antagonist; Vomiting

Indexed keywords

2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 (3 OXO 1 PHOSPHORYL 1,2,4 TRIAZOL 5 YLMETHYL)MORPHOLINE; 3 (2 METHOXY 5 TRIFLUOROMETHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 5 AMINOVALERYLSUBSTANCE P [7-11][9 PROLINE 10 (N METHYLLEUCINE)]; [2 (1H INDOL 3 YLMETHYL) 1 (1 PHENYLETHYLCARBAMOYL)ETHYL]CARBAMIC ACID BENZOFURAN 2 YLMETHYL ESTER; AMIDE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; BIPHENYL DERIVATIVE; CISPLATIN; CYTOTOXIC AGENT; DEXAMETHASONE; EZLOPITANT; GRANISETRON; L 743310; ONDANSETRON; PHYSALAEMIN[9 DEXTRO PROLINE SPIRO GAMMA LACTAM 10 LEUCINE 11 TRYPTOPHAN]; PIPERAZINE DERIVATIVE; PIPERIDINE; PLACEBO; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINIDINE DERIVATIVE; SEROTONIN 3 ANTAGONIST; STEROID; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOFOPITANT; ZD 6021;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIEMETIC ACTIVITY; CANCER CHEMOTHERAPY; CHEMICAL STRUCTURE; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INDUSTRY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERANCE; FERRET; HUMAN; LIBRARY; LIFE EXPECTANCY; NAUSEA; NEOPLASM; NONHUMAN; RAT; REVIEW; TREATMENT OUTCOME;

EID: 0035207423     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.12.1837     Document Type: Review

References (35)

1. Prevention of cisplatin-induced delayed emesis: Still unsatisfactory
2. 3antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration
3. Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: A quantitative systematic review of randomised placebo-controlled trials
4. 3 antagonist in PONV. A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting
5. 3 antagonist in PONV. Efficacy and adverse effects of prophylactic antiemetics during patient-controlled analgesia therapy: A quantitative systematic review
6. 3) receptor antagonists on gastric tachyarrhythmia and the symptoms of motion sickness
7. Functional characterisation by heterologous expression of a novel cloned tachykinin peptide receptor
8. Evidence that the proposed novel human 'neurokinin-4' receptor is pharmacologically similar to the human neurokinin-3 receptor but is not of human origin
9. Distribution of substance P-like immunoreactive fibres and terminals in the medulla oblongata of the human infant
10. Anatomical distribution of substance P-immunoreactive neurons in human brainstem during the first postnatal year
11. Distribution of substance P-like immunoreactive neurons and terminals throughout the nucleus of the solitary tract in the human brainstem
12. Regional distribution of substance P binding sites in the brainstem of the human newborn
13. Responses of neurons of canine area postrema to neurotransmitters and peptides
14. Behavioral and electrophysiological studies of peptide-induced emesis in dogs
15. Towards understanding the aetiology and pathophysiology of the emetic reflex: Novel approaches to antiemetic drugs
16. 1 receptor antagonists is mediated centrally in the ferret
17. 1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret
18. 1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets
19. 1 receptor antagonists may exist in the medullary area adjacent to the semicompact part of the nucleus ambiguus
20. 1 tachykinin receptor antagonist, CP 99,994, in antagonising the acute and delayed emesis induced by cisplatin in the ferret
21. 1 receptor antagonist
22. 1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret
23. 1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets
24. Randomised Phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis
25. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group
26. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone
27. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis
28. 1 receptor antagonist GR205171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery
29. Substance P (Neurokinin-1) antagonist prevents postoperative vomiting after abdominal hysterectomy procedures
30. 3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man
31. Pharmacological Characterisation of ZD6021: A Novel, Orally Active Antagonist of the Tachykinin Receptors
32. 1 receptor antagonists: Optimisation of indole substitution
33. 1 receptor antagonists: Optimisation of the 2-Aryl ring and the indole nitrogen substituent
34. Axially Chiral 1,7-Naphthyridine-6-carboxamide Derivatives as Orally Active Tachykinin Antagonists: Synthesis, Antagonistic Activity, and Effects on Bladder Functions
35. Effects of TAK-637, a Novel Neurokinin-1 Receptor Antagonist, on Colonic Function